Market Overview

Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia


- Company completes End-of-Phase 2 Meeting with FDA -

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and therapeutic
indications, today announced the completion of its End-of-Phase 2
meeting with the U.S. Food and Drug Administration (FDA) along with
receipt of Scientific Advice from the Europe Medicines Agency (EMA)
regarding DaxibotulinumtoxinA for Injection (RT002) for the treatment of
cervical dystonia, a movement disorder of the neck, in adults. Based on
the Phase 2 safety and efficacy results, along with guidance from the
FDA and EMA, Revance plans to proceed to a Phase 3 program in cervical

Revance's Phase 3 program will be conducted at multiple sites in the
U.S., Canada and Europe, and will be designed to fulfill regulatory
submission requirements in both the U.S. and Europe. Revance is
finalizing the trial protocols for the pivotal program, which is planned
to commence in the second quarter of 2018.

In May 2017, the company reported that in a Phase 2 trial, RT002
appeared to be generally safe and well-tolerated, delivered clinically
significant improvement in signs and symptoms of cervical dystonia in
patients, and demonstrated duration of effect of at least 24 weeks.
Earlier this month, the company announced that the FDA granted Orphan
Drug Designation for RT002 to treat cervical dystonia.

"Our discussions with the FDA and EMA were very fruitful, directing
specific courses of action for our clinical program for RT002 in
cervical dystonia," said Dan Browne, President and Chief Executive
Officer of Revance. "We are energized by the momentum behind our first
potential therapeutic indication and are excited by the prospect of
bringing this promising, long-acting therapy to those suffering from
this highly debilitating disease."

About Cervical Dystonia

According to the Dystonia Medical Research Foundation, whose mission is
to advance research, promote awareness and education, and support the
needs of affected individuals, cervical dystonia is a painful condition
in which the neck muscles contract involuntarily, causing abnormal
movements and awkward posture of the head and neck. The movements may be
sustained (tonic), jerky (clonic), or a combination. Cervical dystonia
(also referred to as spasmodic torticollis) may be primary (meaning that
it is the only apparent neurological disorder, with or without a family
history) or may be brought about by secondary causes (such as physical
trauma). It can result in considerable pain and discomfort.

Treatments for cervical dystonia include oral medications, botulinum
toxin injections, surgery, and complementary therapies. Botulinum toxin
can help block the communication between the nerve and the muscle and
may alleviate abnormal movements and postures. Current botulinum toxin
treatments for cervical dystonia have a duration of effect of
approximately three months. Cervical dystonia can occur at any age,
although most individuals first experience symptoms in middle age. The
condition affects a few hundred thousand adults and children in the
United States alone. Revance estimates the global market for treating
muscle movement disorders with botulinum toxins, including cervical
dystonia, was nearly $1 billion in 2015.

About Revance Therapeutics, Inc.

Revance, a Silicon Valley-based biotechnology company, is committed to
the advancement of remarkable science. The company is developing a
portfolio of products for aesthetic medicine and underserved therapeutic
specialties, including dermatology, orthopedics and neurology. Revance's
science is based upon a proprietary peptide technology, which when
combined with active drug molecules, may help address current unmet
needs. Revance's initial focus is on developing daxibotulinumtoxinA, the
company's highly purified botulinum toxin, for a broad spectrum of
aesthetic and therapeutic indications, including facial wrinkles and
muscle movement disorders.

The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis with the potential to be
the first long-acting neuromodulator. The company holds worldwide rights
to RT002 injectable and RT001 topical and the pharmaceutical uses of its
proprietary peptide technology platform. More information on Revance may
be found at

"Revance Therapeutics" and the Revance logo are registered trademarks
of Revance Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including
statements related to the process and timing of, and ability to
complete, current and anticipated future clinical development of our
investigational drug product candidates, including but not limited to
initiation and design of clinical studies for current and future
indications, related results and reporting of such results; statements
about our business strategy, timeline and other goals and market for our
anticipated products, plans and prospects; and statements about our
ability to obtain regulatory approval; and potential benefits of our
drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not limited
to: the outcome, cost, and timing of our product development activities
and clinical trials; the uncertain clinical development process,
including the risk that clinical trials may not have an effective design
or generate positive results; our ability to obtain and maintain
regulatory approval of our drug product candidates; our ability to
obtain funding for our operations; our plans to research, develop, and
commercialize our drug product candidates; our ability to achieve market
acceptance of our drug product candidates; unanticipated costs or delays
in research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the size and
growth potential of the markets for our drug product candidates; our
ability to successfully commercialize our drug product candidates and
the timing of commercialization activities; the rate and degree of
market acceptance of our drug product candidates; our ability to develop
sales and marketing capabilities; the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs for
financing; our ability to continue obtaining and maintaining
intellectual property protection for our drug product candidates; and
other risks. Detailed information regarding factors that may cause
actual results to differ materially from the results expressed or
implied by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange Commission (the
"SEC"), including factors described in the section entitled "Risk
Factors" of our quarterly report on Form 10-Q filed November 3, 2017.
These forward-looking statements speak only as of the date hereof.
Revance disclaims any obligation to update these forward-looking

View Comments and Join the Discussion!